[HTML][HTML] Abiraterone in metastatic prostate cancer without previous chemotherapy
CJ Ryan, MR Smith, JS De Bono… - … England Journal of …, 2013 - Mass Medical Soc
Background Abiraterone acetate, an androgen biosynthesis inhibitor, improves overall
survival in patients with metastatic castration-resistant prostate cancer after chemotherapy. We …
survival in patients with metastatic castration-resistant prostate cancer after chemotherapy. We …
[HTML][HTML] Abiraterone and increased survival in metastatic prostate cancer
…, H Patterson, JD Hainsworth, CJ Ryan… - … England Journal of …, 2011 - Mass Medical Soc
Background Biosynthesis of extragonadal androgen may contribute to the progression of
castration-resistant prostate cancer. We evaluated whether abiraterone acetate, an inhibitor of …
castration-resistant prostate cancer. We evaluated whether abiraterone acetate, an inhibitor of …
[PDF][PDF] Genomic hallmarks and structural variation in metastatic prostate cancer
While mutations affecting protein-coding regions have been examined across many cancers,
structural variants at the genome-wide level are still poorly defined. Through integrative …
structural variants at the genome-wide level are still poorly defined. Through integrative …
[HTML][HTML] Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study
…, L True, A Foye, D Playdle, CJ Ryan… - Journal of Clinical …, 2018 - ncbi.nlm.nih.gov
Purpose The prevalence and features of treatment-emergent small-cell neuroendocrine prostate
cancer (t-SCNC) are not well characterized in the era of modern androgen receptor (AR)…
cancer (t-SCNC) are not well characterized in the era of modern androgen receptor (AR)…
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302) …
CJ Ryan, MR Smith, K Fizazi, F Saad… - The Lancet …, 2015 - thelancet.com
Background Abiraterone acetate plus prednisone significantly improved radiographic
progression-free survival compared with placebo plus prednisone in men with chemotherapy-…
progression-free survival compared with placebo plus prednisone in men with chemotherapy-…
[HTML][HTML] Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3
…, DE Rathkopf, SF Slovin, CJ Ryan… - Journal of Clinical …, 2016 - ncbi.nlm.nih.gov
Purpose Evolving treatments, disease phenotypes, and biology, together with a changing
drug development environment, have created the need to revise castration-resistant prostate …
drug development environment, have created the need to revise castration-resistant prostate …
[HTML][HTML] Rucaparib or physician's choice in metastatic prostate cancer
…, SP Watkins, S Chowdhury, CJ Ryan… - … England Journal of …, 2023 - Mass Medical Soc
Background In a phase 2 study, rucaparib, an inhibitor of poly(ADP-ribose) polymerase (PARP),
showed a high level of activity in patients who had metastatic, castration-resistant …
showed a high level of activity in patients who had metastatic, castration-resistant …
[HTML][HTML] Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration
…, E Voog, J Zhang, JM Piulats, CJ Ryan… - Journal of Clinical …, 2020 - ncbi.nlm.nih.gov
PURPOSE BRCA1 or BRCA2 (BRCA) alterations are common in men with metastatic
castration-resistant prostate cancer (mCRPC) and may confer sensitivity to poly (ADP-ribose) …
castration-resistant prostate cancer (mCRPC) and may confer sensitivity to poly (ADP-ribose) …
[HTML][HTML] Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer
…, MJ Morris, JS De Bono, CJ Ryan… - Journal of Clinical …, 2010 - ncbi.nlm.nih.gov
Purpose Persistence of ligand-mediated androgen receptor signaling has been documented
in castration-resistant prostate cancers (CRPCs). Abiraterone acetate (AA) is a potent and …
in castration-resistant prostate cancers (CRPCs). Abiraterone acetate (AA) is a potent and …
[HTML][HTML] Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received …
CJ Ryan, MR Smith, L Fong, JE Rosenberg… - Journal of clinical …, 2010 - ncbi.nlm.nih.gov
Purpose Abiraterone acetate is a prodrug of abiraterone, a selective inhibitor of CYP17, the
enzyme catalyst for two essential steps in androgen biosynthesis. In castration-resistant …
enzyme catalyst for two essential steps in androgen biosynthesis. In castration-resistant …